−1.54USD
−614.93 MUSD
82.98 M
About Summit Therapeutics Inc.
Sector
Industry
Headquarters
Menlo Park
Website
Employees (FY)
105
Founded
2003
ISIN
US86627T1088
FIGI
BBG00X3GQL76
Summit Therapeutics, Inc. a biopharmaceutical company, which discovers, develops, and commercializes medicines to treat infectious diseases. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Menlo Park, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of SMMT is 3.44 USD — it has decreased by 1.99% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Summit Therapeutics Inc. stocks are traded under the ticker SMMT.
Summit Therapeutics Inc. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
SMMT stock is 4.41% volatile and has beta coefficient of 0.22. Check out the list of the most volatile stocks — is Summit Therapeutics Inc. there?
One year price forecast for Summit Therapeutics Inc. has a max estimate of 8.00 USD and a min estimate of 8.00 USD.
SMMT earnings for the last quarter are −0.14 USD per share, whereas the estimation was −0.26 USD resulting in a 46.15% surprise. The estimated earnings for the next quarter are −0.26 USD per share. See more details about Summit Therapeutics Inc. earnings.
Summit Therapeutics Inc. revenue for the last quarter amounts to 192.00 K USD despite the estimated figure of 4.41 M USD. In the next quarter revenue is expected to reach 4.45 M USD.
Yes, you can track Summit Therapeutics Inc. financials in yearly and quarterly reports right on TradingView.
SMMT stock has fallen by 14.21% compared to the previous week, the month change is a 5.75% fall, over the last year Summit Therapeutics Inc. has showed a 115.00% increase.
SMMT net income for the last quarter is −36.60 M USD, while the quarter before that showed −21.27 M USD of net income which accounts for −72.09% change. Track more Summit Therapeutics Inc. financial stats to get the full picture.
Today Summit Therapeutics Inc. has the market capitalization of 2.46 B, it has increased by 2.60% over the last week.
No, SMMT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, SMMT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Summit Therapeutics Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 105.00 employees. See our rating of the largest employees — is Summit Therapeutics Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Summit Therapeutics Inc. technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Summit Therapeutics Inc. stock shows the neutral signal. See more of Summit Therapeutics Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Summit Therapeutics Inc. future price: according to them, SMMT price has a max estimate of 8.00 USD and a min estimate of 8.00 USD. Read a more detailed Summit Therapeutics Inc. forecast: see what analysts think of Summit Therapeutics Inc. and suggest that you do with its stocks.